The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Atezolizumab with R-GEMOX in patients with transformed DLBCL
Alex Herrera, MD, City of Hope, Duarte, CA, shares an update on the study evaluating the addition of the PD-L1 inhibitor, atezolizumab, to immunogenic chemoimmunotherapy, rituximab with gemcitabine and oxaliplatin (R-GEMOX) in patients with relapsed/refractory (R/R) transformed diffuse large b-cell lymphoma (DLBCL) or Richter transformation (RT) from chronic lymphocytic leukemia (CLL). While patients with RT did not show outstanding responses, the patients with transformed follicular lymphoma and transformed marginal zone lymphoma presented good response rates. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
